Related Experiment Video
Updated: Jun 27, 2025
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
Somatic Mutations in Surgically Treated Colorectal Liver Metastases: An Overview
Jane Wang1, Julia Botvinov2, Aarshvi Jahnvi Bhatt3
1Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Abstract:
Colorectal cancer is the second most common cause of cancer death in the United States, and up to half of patients develop colorectal liver metastases (CRLMs). Notably, somatic genetic mutations, such as mutations in RAS, BRAF, mismatch repair (MMR) genes, TP53, and SMAD4, have been shown to play a prognostic role in patients with CRLM. This review summarizes and appraises the current literature regarding the most relevant somatic mutations in surgically treated CRLM by not only reviewing representative studies, but also providing recommendations for areas of future research. In addition, advancements in genetic testing and an increasing emphasis on precision medicine have led to a more nuanced understanding of these mutations; thus, more granular data for each mutation are reviewed when available. Importantly, such knowledge can pave the way for precision medicine with the ultimate goal of improving patient outcomes.
Insights
Somatic mutations in colorectal liver metastases (CRLM) impact patient prognosis. Understanding these genetic changes, including RAS, BRAF, and MMR genes, is key for developing precision medicine strategies to improve outcomes.
Area of Science:
- Oncology
- Genetics
- Surgical Pathology
Background:
- Colorectal cancer (CRC) is a leading cause of cancer mortality in the US.
- Colorectal liver metastases (CRLM) affect up to 50% of CRC patients.
- Somatic genetic mutations influence CRLM prognosis.
Purpose of the Study:
- To review and appraise current literature on prognostic somatic mutations in surgically treated CRLM.
- To provide recommendations for future research directions.
- To highlight the role of genetic mutations in advancing precision medicine for CRLM.
Main Methods:
- Comprehensive literature review of studies on surgically treated CRLM.
- Analysis of prognostic roles of specific somatic mutations (e.g., RAS, BRAF, MMR, TP53, SMAD4).
- Inclusion of granular data on mutations where available.
Main Results:
- Identified key somatic mutations (RAS, BRAF, MMR, TP53, SMAD4) with prognostic significance in CRLM.
- Highlighted advancements in genetic testing enabling a nuanced understanding of these mutations.
- Emphasized the growing importance of precision medicine in tailoring treatments.
Conclusions:
- Knowledge of CRLM somatic mutations is crucial for personalized treatment strategies.
- Further research is needed to refine our understanding and application of genetic data in CRLM management.
- Precision medicine approaches hold significant promise for improving patient outcomes in CRLM.
